中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(8): 1999-2004

Role of Golgi protein 73(GP73) in diagnosis of chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.08.035
  • 1.

    Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

  • 2.

    Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China

  • 3.

    Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81730109);

National Natural Science Foundation of China (82274305);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201);

Shanghai Science and Technology Commission (22YF1449300);

Shanghai University of TCM Budget Project (2021LK081)

More Information
  • Corresponding author: LIU Chenghai, chenghailiu@hotmail.com (0000-0002-1696-6008)
  • Received Date: 2022-11-08
  • Accepted Date: 2022-12-08
  • Published Date: 2023-08-20
    Abstract
  • Early diagnosis and accurate assessment of liver inflammation and fibrosis is particularly important for the therapeutic intervention and prognosis of chronic liver diseases. This article summarizes the diagnostic efficacy of Golgi protein 73 (GP73) for chronic liver diseases by reviewing related clinical studies on GP73 and the diagnosis and prognosis of liver cancer, liver fibrosis, and liver inflammation. The analysis shows that besides liver cancer, GP73 is closely associated with the degree of liver fibrosis and prognosis and can better reflect liver inflammatory damage. GP73 combined with other serum markers can improve the noninvasive diagnosis of chronic liver diseases.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
    [2]
    KLADNEY RD, BULLA GA, GUO L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene, 2000, 249(1-2): 53-65. DOI: 10.1016/s0378-1119(00)00136-0.
    [3]
    LIU XY, FAN ZJ, ZHOU C, et al. Expression and clinical significance of Golgi protein 73 and Ki-67 in gallbladder carcinoma[J]. J Prac Med, 2017, 33(1): 47-50. DOI: 10.3969/j.issn.1006-5725.2017.01.013.

    刘星雨, 范正军, 周闯, 等. 高尔基体蛋白GP73和Ki-67在胆囊癌中的表达及临床意义[J]. 实用医学杂志, 2017, 33(1): 47-50. DOI: 10.3969/j.issn.1006-5725.2017.01.013.
    [4]
    KRISTIANSEN G, FRITZSCHE FR, WASSERMANN K, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics[J]. Br J Cancer, 2008, 99(6): 939-948. DOI: 10.1038/sj.bjc.6604614.
    [5]
    LIANG R, LIU Z, PIAO X, et al. Research progress on GP73 in malignant tumors[J]. Onco Targets Ther, 2018, 11: 7417-7421. DOI: 10.2147/OTT.S181239.
    [6]
    XIA Y, ZHANG Y, SHEN M, et al. Golgi protein 73 and its diagnostic value in liver diseases[J]. Cell Prolif, 2019, 52(2): e12538. DOI: 10.1111/cpr.12538.
    [7]
    KLADNEY RD, CUI X, BULLA GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease[J]. Hepatology, 2002, 35(6): 1431-1440. DOI: 10.1053/jhep.2002.32525.
    [8]
    YE QH, ZHU WW, ZHANG JB, et al. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis[J]. Cancer Cell, 2016, 30(3): 444-458. DOI: 10.1016/j.ccell.2016.07.017.
    [9]
    IFTIKHAR R, KLADNEY RD, HAVLIOGLU N, et al. Disease- and cell-specific expression of GP73 in human liver disease[J]. Am J Gastroenterol, 2004, 99(6): 1087-1095. DOI: 10.1111/j.1572-0241.2004.30572.x.
    [10]
    MANNAERTS I, SCHROYEN B, VERHULST S, et al. Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration[J]. PLoS One, 2013, 8(12): e84071. DOI: 10.1371/journal.pone.0084071.
    [11]
    WANG S, JUNG Y, HYUN J, et al. RNA binding proteins control transdifferentiation of hepatic stellate cells into myofibroblasts[J]. Cell Physiol Biochem, 2018, 48(3): 1215-1229. DOI: 10.1159/000491987.
    [12]
    MA LY, ZHEN YN, LUO YP, et al. Expression and mechanism of gp73 in liver tissure of mouse liver fibrosis[J]. Basic Clin Med, 2020, 40(6): 771-776. DOI: 10.16352/j.issn.1001-6325.2020.06.005.

    马玲玉, 甄一宁, 罗云萍, 等. gp73在小鼠肝纤维化肝组织中的表达及机制[J]. 基础医学与临床, 2020, 40(6): 771-776. DOI: 10.16352/j.issn.1001-6325.2020.06.005.
    [13]
    YAO M, WANG L, LEUNG P, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review[J]. Clin Rev Allergy Immunol, 2018, 54(2): 282-294. DOI: 10.1007/s12016-017-8655-y.
    [14]
    WAN LM, GAO Q, DENG YQ, et al. GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia[J]. Nat Metab, 2022, 4(1): 29-43. DOI: 10.1038/s42255-021-00508-2.
    [15]
    YANG X, WU F, CHEN J, et al. GP73 regulates Hepatic Steatosis by enhancing SCAP-SREBPs interaction[J]. Sci Rep, 2017, 7(1): 14932. DOI: 10.1038/s41598-017-06500-9.
    [16]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [17]
    SONG PP, XIA JF, INAGAKI Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(1): 262-274. DOI: 10.3748/wjg.v22.i1.262.
    [18]
    MARRERO JA, ROMANO PR, NIKOLAEVA O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma[J]. J Hepatol, 2005, 43(6): 1007-1012. DOI: 10.1016/j.jhep.2005.05.028.
    [19]
    BLOCK TM, COMUNALE MA, LOWMAN M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J]. Proc Natl Acad Sci U S A, 2005, 102(3): 779-784. DOI: 10.1073/pnas.0408928102.
    [20]
    MAO Y, YANG H, XU H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12): 1687-1693. DOI: 10.1136/gut.2010.214916.
    [21]
    BAO YX, YANG Y, ZHAO HR, et al. Clinical significance and diagnostic value of Golgi-protein 73 in patients with early-stage primary hepatocellular carcinoma[J]. Chin J Oncol, 2013, 35(7): 505-508. DOI: 10.3760/cma.j.issn.0253-3766.2013.07.006.

    包永星, 杨颖, 赵化荣, 等. 高尔基体蛋白73对早期肝癌的诊断价值及临床意义[J]. 中华肿瘤杂志, 2013, 35(7): 505-508. DOI: 10.3760/cma.j.issn.0253-3766.2013.07.006.
    [22]
    KE MY, WU XN, ZHANG Y, et al. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma[J]. J Transl Med, 2019, 17(1): 140. DOI: 10.1186/s12967-019-1889-0.
    [23]
    DONG MC, BAI J, LIU HS, et al. The clinical application of serum GPC3, DCP, GP73, and AFP in hepatocellular carcinoma[J]. Labeled Immunoassays Clin Med, 2022, 29(7): 1142-1147. DOI: 10.11748/bjmy.issn.1006-1703.2022.07.013.

    董美衬, 白晶, 刘海顺, 等. 血清GPC3、DCP、GP73及AFP联合检测在原发性肝癌的诊断价值[J]. 标记免疫分析与临床, 2022, 29(7): 1142-1147. DOI: 10.11748/bjmy.issn.1006-1703.2022.07.013.
    [24]
    CUI Q, DONG YE, HUO YL, et al. Simultaneous detection of serum AFP, GP73, SF and DCP in the diagnosis of primary liver cancer[J]. J China Med Univ, 2019, 48(5): 434-436. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYK201905013.htm

    崔琦, 董延娥, 霍云龙, 等. 血清AFP、GP73、SF、DCP联合检测在原发性肝癌诊断中的应用[J]. 中国医科大学学报, 2019, 48(5): 434-436. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYK201905013.htm
    [25]
    ZHANG Z, ZHANG Y, WANG Y, et al. Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma[J]. Onco Targets Ther, 2016, 9: 123-129. DOI: 10.2147/OTT.S90732.
    [26]
    GATSELIS NK, TORNAI T, SHUMS Z, et al. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients[J]. World J Gastroenterol, 2020, 26(34): 5130-5145. DOI: 10.3748/wjg.v26.i34.5130.
    [27]
    DONG M, CHEN ZH, LI X, et al. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma[J]. Oncol Lett, 2017, 14(5): 6277-6284. DOI: 10.3892/ol.2017.6938.
    [28]
    LU FM. Serological diagnosis of hepatocellular carcinoma: challenges and opportunities[J]. J Clin Hepatol, 2017, 33(7): 1262-1265. DOI: 10.3969/j.issn.1001-5256.2017.07.011.

    鲁凤民. 肝细胞癌的血清学诊断——挑战与希望同在[J]. 临床肝胆病杂志, 2017, 33(7): 1262-1265. DOI: 10.3969/j.issn.1001-5256.2017.07.011.
    [29]
    LIU TH, YAO MJ, LIU SH, et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma[J]. Oncotarget, 2017, 8(10): 16498-16506. DOI: 10.18632/oncotarget.14954.
    [30]
    YAO M, WANG L, YOU H, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B[J]. Clin Chim Acta, 2019, 493: 92-97. DOI: 10.1016/j.cca.2019.02.019.
    [31]
    LIU L, WANG J, FENG J, et al. Serum Golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease[J]. Sci Rep, 2018, 8(1): 16730. DOI: 10.1038/s41598-018-34714-y.
    [32]
    WANG PF, LIU SH, QIAN XJ, et al. The diagnostic potential of Golgi protein 73 for cirrhosis in patients with chronic hepatitis C[J]. Chin J Hepatol, 2022, 30(8): 879-884. DOI: 10.3760/cma.j.cn501113-20200415-00186.

    王鹏飞, 刘树红, 钱相君, 等. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究[J]. 中华肝脏病杂志, 2022, 30(8): 879-884. DOI: 10.3760/cma.j.cn501113-20200415-00186.
    [33]
    LIU FM, ZHANG Y. Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis[J]. Chin J Hepatol, 2018, 26(5): 321-324. DOI: 10.3760/cma.j.issn.1007-3418.2018.05.001.

    鲁凤民, 张芸. 血清高尔基体糖蛋白73在肝硬化诊断中的应用及其相关机制[J]. 中华肝脏病杂志, 2018, 26(5): 321-324. DOI: 10.3760/cma.j.issn.1007-3418.2018.05.001.
    [34]
    XU Z, LIU L, PAN X, et al. Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease[J]. Medicine (Baltimore), 2015, 94(12): e659. DOI: 10.1097/MD.0000000000000659.
    [35]
    WEI M, XU Z, PAN X, et al. Serum GP73 - an additional biochemical marker for liver inflammation in chronic HBV infected patients with normal or slightly raised ALT[J]. Sci Rep, 2019, 9(1): 1170. DOI: 10.1038/s41598-018-36480-3.
    [36]
    YAO MJ, WANG LJ, GUAN GW, et al. Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B[J]. J Clin Hepatol, 2018, 34(4): 755-759. DOI: 10.3969/j.issn.1001-5256.2018.04.012.

    姚明解, 王雷婕, 关贵文, 等. 血清高尔基体蛋白73在辅助诊断慢性乙型肝炎患者中度以上肝损伤中的应用[J]. 临床肝胆病杂志, 2018, 34(4): 755-759. DOI: 10.3969/j.issn.1001-5256.2018.04.012.
    [37]
    FENG ZG, CEN XH, YUN JM, et al. Diagnostic value of GP73 in alcoholic liver disease[J]. Int J Lab Med, 2015, 36(15): 2214-2215, 2217. DOI: 10.3969/j.issn.1673-4130.2015.15.037.

    冯志刚, 岑晓红, 云俊木, 等. GP73在酒精性肝病中的临床意义[J]. 国际检验医学杂志, 2015, 36(15): 2214-2215, 2217. DOI: 10.3969/j.issn.1673-4130.2015.15.037.
    [38]
    WANG L, YAO M, LIU S, et al. Serum golgi protein 73 as a potential biomarker for hepatic necroinflammation in population with nonalcoholic steatohepatitis[J]. Dis Markers, 2020, 2020: 6036904. DOI: 10.1155/2020/6036904.
    [39]
    LI Y, YANG Y, LI Y, et al. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis[J]. J Int Med Res, 2021, 49(11): 3000605211055378. DOI: 10.1177/03000605211055378.
    [40]
    YAO M, WANG L, WANG J, et al. Diagnostic value of serum golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis[J]. Dis Markers, 2022, 2022: 4253566. DOI: 10.1155/2022/4253566.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (562) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return